-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] The first day of A-share IPOs has become a hot topic of market concern and discussion
.
It is understood that there has been a "breaking wave" of new pharmaceutical stocks recently.
Among them, a number of new pharmaceutical A shares have been listed since April alone, and many new stocks have broken
.
For example, on April 25, Jicui Yaokang successfully landed on the Science and Technology Innovation Board with an issue price of 22.
53 yuan per share, and the net amount of funds raised was 1.
026 billion yuan
.
According to the issue price, its market value is 9.
237 billion yuan
.
On the first day of listing, the stock opened at 20.
00 yuan per share, and it broke at the opening
.
According to the prospectus, Yaokang Bio is an enterprise specializing in the research and development, production, sales and related technical services of experimental animal mouse models
.
Up to now, Jicui Yaokang has developed and constructed a genetically engineered mouse model construction platform, innovative drug screening and phenotype analysis platform, Mouse breeding and germplasm preservation platform and germ-free mice and flora colonization platform
.
On April 12, the first trading day of the listing of Haichuang Pharmaceutical, a new stock on the Science and Technology Innovation Board, broke at the opening.
The issue price of the stock was 42.
92 yuan per share, and the opening price was 41.
00 yuan per share.
It then fell all the way down and closed down 29.
87%
.
According to the issue price of 42.
92 yuan per share, and the first signing of 500 shares, the loss of the first signing is 6410 yuan
.
According to the data, Haichuang Pharmaceutical is an innovative drug research and development enterprise focusing on major therapeutic fields such as tumors and metabolic diseases
.
As of the prospectus signing date, the company has 10 main products under development, of which 9 are new drugs independently developed and 1 is a new drug introduced through cooperation
.
On April 7, Tianyi Medical was listed on the GEM of the Shenzhen Stock Exchange at an issue price of 52.
37 yuan per share, which broke at the opening
.
On the same day, the stock opened at 49.
98 yuan, down 4.
56%, and closed at 63.
33 yuan, up 20.
93%
.
According to public information, Tianyi Medical is an enterprise mainly engaged in the research and development, production and sales of medical devices such as medical polymer consumables in the fields of blood purification and ward nursing
.
The company plans to raise 510 million yuan in this IPO.
The raised funds are mainly used for the construction project of blood purification equipment with an annual output of 40 million sets, the construction project of sterile humidification and oxygen absorption device with an annual output of 10 million sets, the construction project of R&D center and the supplementary working capital.
.
According to incomplete statistics, there have been more than 90 new pharmaceutical stocks listed since 2022, but more than half of them have broken
.
So, why do new pharmaceutical stocks set off a "break wave"? From the perspective of the industry, whether the price of new shares rises or falls on the first day of listing is related to the influence of multiple factors such as company value, issue price, macro environment, and market fluctuations
.
Regarding the frequent breaking of new pharmaceutical stocks, some industry analysts pointed out that, on the one hand, it is affected by factors such as market fluctuations and the comprehensive promotion of the registration system; To a certain extent, the new price regulation has pushed up the pricing of new shares, which has led to a decline in the income of new shares, and more cautious funds involved in new sales, forcing investment institutions to improve their investment and research capabilities.
The breaking of new shares is actually a process of market rationality
.
It is worth mentioning that the high proportion of new shares breaking has also attracted the attention of the regulatory authorities
.
Recently, the Shanghai Stock Exchange organized a number of securities companies to hold a symposium, at which the current market breakout phenomenon was discussed
.
The Shanghai Stock Exchange said that in the next step, it will consider including indicators such as "large proportion of breakouts" into the evaluation of the quality of practice of lead underwriters.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is understood that there has been a "breaking wave" of new pharmaceutical stocks recently.
Among them, a number of new pharmaceutical A shares have been listed since April alone, and many new stocks have broken
.
For example, on April 25, Jicui Yaokang successfully landed on the Science and Technology Innovation Board with an issue price of 22.
53 yuan per share, and the net amount of funds raised was 1.
026 billion yuan
.
According to the issue price, its market value is 9.
237 billion yuan
.
On the first day of listing, the stock opened at 20.
00 yuan per share, and it broke at the opening
.
According to the prospectus, Yaokang Bio is an enterprise specializing in the research and development, production, sales and related technical services of experimental animal mouse models
.
Up to now, Jicui Yaokang has developed and constructed a genetically engineered mouse model construction platform, innovative drug screening and phenotype analysis platform, Mouse breeding and germplasm preservation platform and germ-free mice and flora colonization platform
.
On April 12, the first trading day of the listing of Haichuang Pharmaceutical, a new stock on the Science and Technology Innovation Board, broke at the opening.
The issue price of the stock was 42.
92 yuan per share, and the opening price was 41.
00 yuan per share.
It then fell all the way down and closed down 29.
87%
.
According to the issue price of 42.
92 yuan per share, and the first signing of 500 shares, the loss of the first signing is 6410 yuan
.
According to the data, Haichuang Pharmaceutical is an innovative drug research and development enterprise focusing on major therapeutic fields such as tumors and metabolic diseases
.
As of the prospectus signing date, the company has 10 main products under development, of which 9 are new drugs independently developed and 1 is a new drug introduced through cooperation
.
On April 7, Tianyi Medical was listed on the GEM of the Shenzhen Stock Exchange at an issue price of 52.
37 yuan per share, which broke at the opening
.
On the same day, the stock opened at 49.
98 yuan, down 4.
56%, and closed at 63.
33 yuan, up 20.
93%
.
According to public information, Tianyi Medical is an enterprise mainly engaged in the research and development, production and sales of medical devices such as medical polymer consumables in the fields of blood purification and ward nursing
.
The company plans to raise 510 million yuan in this IPO.
The raised funds are mainly used for the construction project of blood purification equipment with an annual output of 40 million sets, the construction project of sterile humidification and oxygen absorption device with an annual output of 10 million sets, the construction project of R&D center and the supplementary working capital.
.
According to incomplete statistics, there have been more than 90 new pharmaceutical stocks listed since 2022, but more than half of them have broken
.
So, why do new pharmaceutical stocks set off a "break wave"? From the perspective of the industry, whether the price of new shares rises or falls on the first day of listing is related to the influence of multiple factors such as company value, issue price, macro environment, and market fluctuations
.
Regarding the frequent breaking of new pharmaceutical stocks, some industry analysts pointed out that, on the one hand, it is affected by factors such as market fluctuations and the comprehensive promotion of the registration system; To a certain extent, the new price regulation has pushed up the pricing of new shares, which has led to a decline in the income of new shares, and more cautious funds involved in new sales, forcing investment institutions to improve their investment and research capabilities.
The breaking of new shares is actually a process of market rationality
.
It is worth mentioning that the high proportion of new shares breaking has also attracted the attention of the regulatory authorities
.
Recently, the Shanghai Stock Exchange organized a number of securities companies to hold a symposium, at which the current market breakout phenomenon was discussed
.
The Shanghai Stock Exchange said that in the next step, it will consider including indicators such as "large proportion of breakouts" into the evaluation of the quality of practice of lead underwriters.
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
